These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29680234)

  • 1. Rational Design of Liquid Formulations of Proteins.
    Manning MC; Liu J; Li T; Holcomb RE
    Adv Protein Chem Struct Biol; 2018; 112():1-59. PubMed ID: 29680234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The stability factor: importance in formulation development.
    Krishnamurthy R; Manning MC
    Curr Pharm Biotechnol; 2002 Dec; 3(4):361-71. PubMed ID: 12463418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive Screening Tools Used in High-Concentration Protein Formulation Development.
    Hofmann M; Gieseler H
    J Pharm Sci; 2018 Mar; 107(3):772-777. PubMed ID: 29102552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic Investigation on Grinding-Induced Subvisible Particle Formation during Mixing and Filling of Monoclonal Antibody Formulations.
    Gikanga B; Hui A; Maa YF
    PDA J Pharm Sci Technol; 2018; 72(2):117-133. PubMed ID: 29030532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proximity energies: a framework for understanding concentrated solutions.
    Laue T
    J Mol Recognit; 2012 Mar; 25(3):165-73. PubMed ID: 22407980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amino Acid-Based Advanced Liquid Formulation Development for Highly Concentrated Therapeutic Antibodies Balances Physical and Chemical Stability and Low Viscosity.
    Kemter K; Altrichter J; Derwand R; Kriehuber T; Reinauer E; Scholz M
    Biotechnol J; 2018 Jul; 13(7):e1700523. PubMed ID: 29663661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational design of lyophilized high concentration protein formulations-mitigating the challenge of slow reconstitution with multidisciplinary strategies.
    Cao W; Krishnan S; Ricci MS; Shih LY; Liu D; Gu JH; Jameel F
    Eur J Pharm Biopharm; 2013 Oct; 85(2):287-93. PubMed ID: 23702275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-concentration protein formulations: How high is high?
    Garidel P; Kuhn AB; Schäfer LV; Karow-Zwick AR; Blech M
    Eur J Pharm Biopharm; 2017 Oct; 119():353-360. PubMed ID: 28690199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biopharmaceutical liquid formulation: a review of the science of protein stability and solubility in aqueous environments.
    Bye JW; Platts L; Falconer RJ
    Biotechnol Lett; 2014 May; 36(5):869-75. PubMed ID: 24557073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of sorbitol and residual moisture on the stability of lyophilized antibodies: Implications for the mechanism of protein stabilization in the solid state.
    Chang LL; Shepherd D; Sun J; Tang XC; Pikal MJ
    J Pharm Sci; 2005 Jul; 94(7):1445-55. PubMed ID: 15920766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-throughput assessment of thermal and colloidal stability parameters for monoclonal antibody formulations.
    He F; Woods CE; Becker GW; Narhi LO; Razinkov VI
    J Pharm Sci; 2011 Dec; 100(12):5126-41. PubMed ID: 21789772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.
    Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
    J Biomol Screen; 2014 Oct; 19(9):1290-301. PubMed ID: 25023322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in the development of high protein concentration formulations.
    Shire SJ; Shahrokh Z; Liu J
    J Pharm Sci; 2004 Jun; 93(6):1390-402. PubMed ID: 15124199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microfluidic Approaches for the Characterization of Therapeutic Proteins.
    Kopp MRG; Arosio P
    J Pharm Sci; 2018 May; 107(5):1228-1236. PubMed ID: 29325925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Formulation Development Approach to Identify and Select Stable Ultra-High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities.
    Whitaker N; Xiong J; Pace SE; Kumar V; Middaugh CR; Joshi SB; Volkin DB
    J Pharm Sci; 2017 Nov; 106(11):3230-3241. PubMed ID: 28668340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions.
    Nichols P; Li L; Kumar S; Buck PM; Singh SK; Goswami S; Balthazor B; Conley TR; Sek D; Allen MJ
    MAbs; 2015; 7(1):212-30. PubMed ID: 25559441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ReFOLD assay for protein formulation studies and prediction of protein aggregation during long-term storage.
    Svilenov H; Winter G
    Eur J Pharm Biopharm; 2019 Apr; 137():131-139. PubMed ID: 30818009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Filling of High-Concentration Monoclonal Antibody Formulations into Pre-filled Syringes: Investigating Formulation-Nozzle Interactions To Minimize Nozzle Clogging.
    Shieu W; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2015; 69(3):417-26. PubMed ID: 26048747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of formulation variables on protein stability and integrity of a model IgG4 monoclonal antibody and translation to formulation of a model ScFv.
    Gourbatsi E; Povey JF; Smales CM
    Biotechnol Lett; 2018 Jan; 40(1):33-46. PubMed ID: 28939995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concentration-dependent changes in apparent diffusion coefficients as indicator for colloidal stability of protein solutions.
    Bauer KC; Göbel M; Schwab ML; Schermeyer MT; Hubbuch J
    Int J Pharm; 2016 Sep; 511(1):276-287. PubMed ID: 27421911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.